Glenmede Director of Investment Strategy Jason Pride, iSectors CIO Chuck Self and OptionPit.com founder Mark Sebastian on the outlook for the markets.
Kanaly Trust Chairman Drew Kanaly, Royal Oak Financial Group Managing Partner Matt Jehn and SFG Alternatives CIO Larry Shover on the opportunities in the markets for investors.
Glenmede Director of Investment Strategy Jason Pride, Wall Financial Group’s Michael Wall and OptionPit.com founder Mark Sebastian on where the opportunities are for investors.
Rosenthal Wealth Management Group President Larry Rosenthal, Platinum Partners President Uri Landesman and Tethys Partners Chief Market Strategist Bob Iaccino on the markets.
BlackRock chief investment strategist Russ Koesterich and Bianco Research president Jim Bianco on the state of the markets.
STA Wealth Management Chief Strategist Lance Roberts, USAA Investments V.P. John Toohey and Athena Advisor Services’ Dan Stecich on the outlook for the markets.
Earnings HQ: FBN’s Jo Ling Kent breaks down Abbott Laboratories ’ first-quarter earnings report.
Abbott Laboratories Inc reported better-than-expected quarterly earnings, but sales came in slightly below Wall Street expectations.The company on Wednesday said it ...
Glenmede Director of Investment Strategy Jason Pride, Janney Capital Markets Technical Research Director Dan Wantrobski and Altimus Capital Director of Portfolio Management Chris Gersch on the stocks to boost investors’ portfolios.
Novartis Chief Executive Joe Jimenez is taking a hard look at the drugmaker's smaller businesses as he reshapes the company for what he expects to be a "brutal" new ...
Third Point, headed by billionaire fund manager Dan Loeb, has put more money into struggling mobile device makers. According to a 13-f filing released late Friday by...
Abbott Laboratories Inc reported weaker-than-expected fourth-quarter revenue, hurt by the stronger dollar and an overseas sales disruption last summer of its baby fo...
AbbVie Inc on Friday reported stronger-than-expected results for the third quarter, as booming sales of its Humira arthritis treatment and Synthroid thyroid replacem...
Mylan CEO Heather Bresch discusses the company’s impact on the health care industry, its deal with Abbott Laboratories , future developments and the FDA.
Glenmede Director of Investment Strategy Jason Pride and Teddy Weisberg of Seaport Securities discuss the state of the markets and where to invest.
FBN’s Charles Payne, Stifel Nicolaus Portfolio Manager Chad Morganlander and Penn Financial Group founder Matt McCall on the outlook for Trinity Industries.
UK Min. of State for Trade & Investment Lord Ian Livingston on the country’s plan to attract U.S. and foreign business.
FBN’s Liz MacDonald on deal stocks under pressure as the U.S. announces stricter tax rules.
Chapwood Investments’ Ed Butowsky and The Wall Street Journal Editorial Board’s Mary Kissel discuss the significance of AbbVie’s purchase of Ireland’s Shire.
Earnings HQ: FBN’s Adam Shapiro breaks down U.S. Bancorp’s second-quarter earnings report.